Chief Executive Officer
Flemming assumed the position of Shire's chief executive officer on April 30, 2013 and has been a member of the board since January 2, 2013. He is also a member of the company's Executive Committee.
Flemming brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector.
He formerly held the position of Non-Executive Chairman of Evotec AG, and of Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer.
Prior to this, from 2008 to 2010, Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006.
Earlier in his pharmaceutical career Flemming had roles of increasing responsibility at Merck & Co, and Novartis AG, following a distinguished period spent in hospitals and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.